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 Background We investigated whether Makorin ring finger protein 1 (MKRN1), an E3 ligase, affects p14ARF-associated cellular 
senescence and tumorigenesis by posttranslational modification in gastric tumorigenesis.
 Methods A link between MKRN1 and ARF was examined in MKRN1 null mouse embryonic fibroblasts (MEFs) and in human 
fibroblasts and gastric cancer cells by silencing MKRN1 using small interfering RNA (siRNA) and short hairpin 
RNA (shRNA). Ubiquitination and proteasomal degradation assays were used to assess p14ARF degradation 
associated with MKRN1. MKRN1 and p14ARF expression levels were analyzed with immunohistochemistry in 
malignant and normal tissues from gastric cancer patients and with χ2 tests. The tumor growth of gastric can-
cer cells stably expressing MKRN1 shRNA, p14ARF shRNA, or both was examined in mouse xenograft models 
(n = 4–6) and analyzed with unpaired t tests. All statistical tests were two-sided.
 Results MKRN1 knockout MEFs exhibited premature senescence and growth retardation with increased p19ARF protein 
expression. Similar results were obtained for human fibroblasts or gastric cancer cell lines by MKRN1 knock-
down. Biochemical analyses confirmed that MKRN1 targets p14ARF for ubiquitination and subsequent proteas-
ome-dependent degradation. A statistically significant association was shown between MKRN1 overexpression 
and p14ARF underexpression (P = .016). Xenograft analyses using p53-functional AGS or -dysfunctional SNU601 
cells displayed statistically significant tumor growth retardation by silencing MKRN1, which was reversed under 
depletion of p14ARF (AGS cells, MKRN1 knockdown tumors vs MKRN1 and p14ARF knockdown tumors: 164.6 vs 
464.8 mm3, difference = 300.2 mm3, 95% CI = 189.1 to 411.3 mm3, P < .001).
 Conclusions We demonstrated that MKRN1 functions as a novel E3 ligase of p14ARF and that it potentially regulates cellular 
senescence and tumorigenesis in gastric cancer.
  J Natl Cancer Inst 2012;104:1660–1672
ARF (Alternative reading frame; p14ARF in humans and p19ARF 
in mice) is a product of the CDKN2/INK4a/ARF locus, which also 
encodes p16INK4a (1,2). Upon activation, ARF breaks the p53/
Mdm2 feedback loop by sequestering Mdm2 into the nucleolus, 
freeing p53 from its negative regulatory circuit, and therefore pro-
motes oncogene-induced senescence (3–5). ARF also functions 
as a tumor-suppressive regulator separate from the ARF/p53 axis 
through interactions with a variety of proteins including NPM and 
HIF1, allowing versatile roles as a tumor suppressor (6–9). These 
were previously confirmed in ARF knockout mice, which display a 
predisposition toward cancer development at an early age (10,11). 
Until recently, the loss of p14ARF function in various cancers, 
including gastric tumors, was believed to be caused by INK4a/ARF 
locus deletion or silencing triggered by promoter hypermethyla-
tion (12–16). The possibility that the posttranslational modifica-
tion of p14ARF regulated its protein stability was also addressed, 
but only through a handful of reports implicating degradation of 
p14ARF through N-terminal ubiquitination (17,18). Moreover, the 
direct effects of p14ARF modification in tumorigenesis have not 
been defined.
Makorin ring finger protein 1 (MKRN1) is the source gene of 
the intronless MKRN gene family, and it shows high sequence 
conservation from invertebrates to vertebrates (19). It is a zinc-
finger protein that was first identified as an E3 ligase for hTERT 
(20). In a previous report, we showed that MKRN1 simultaneously 
induces p53 and p21 ubiquitination and proteasome-dependent 
degradation. This suggests that the presence of MKRN1 in cancer 
cells might affect p53- and p21-dependent apoptosis and cell 
growth (21).
In this study, we found that MKRN1 could function as an E3 
ligase of p14ARF. MKRN1-knockout mouse embryonic fibroblasts 
(MEFs) or ablation of MKRN1 in gastric cancer cells induced sta-
bilization of p14ARF (p19ARF in mouse), resulting in cellular sen-
escence and growth retardation. Ablation of p14ARF rescued the 
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cell growth that was inhibited by MKRN1 depletion. The same 
observations were accomplished via xenografted mouse mod-
els. Moreover, inverse associations between expression levels of 
MKRN1 and p14ARF were determined in the tissues of human 
gastric cancer patients. Based on these results, we suggest that 
MKRN1 could affect gastric tumorigenesis by repressing cellular 
senescence and tumor-suppressive effects through downregulation 
of p14ARF in a p53-dependent or -independent manner.
Materials and Methods
Plasmids, Small Interfering RNA (siRNA), and Antibodies
pEGFP-N1 containing p14ARF was obtained from FHGB (21C 
Frontier Human Gene Bank, Seoul, South Korea). p14ARF 
WT-3XFLAG/CMV and p14ARF deletion mutants (1–64 and 
65–132)-3XFLAG/CMV were prepared by PCR. MKRN1 cDNA 
and its mutants were as reported previously (21,22). pEGFP-C2 
used as a transfection control was from Clontech (San Diego, CA). 
MKRN1 siRNA #5 (5′-CAGGCGAAGCTGAGTCAAGAA-3′), 
#6 (5′-CGGGATCCTCTCCAACTGCAA-3′), #7 (5′-caggcgaa 
gctgagtcaag-3′), p14ARF siRNA #1 (5′-GAACAUGGUGCGCA 
GGUUCTT-3′), and control siRNA were made by Qiagen-
Xeragon (Valencia, CA). MKRN1 short hairpin RNA (shRNA) 
#2 (TRCN0000033796), #5 (TRCN0000296491), and p14ARF 
shRNA (TRCN00000010482) were purchased from Sigma-Aldrich 
(St Louis, MO). Polyclonal rabbit anti-HA (Y-11) (1:1000 dilution), 
monoclonal mouse anti-HA (F-7) (1:1000 dilution), and polyclonal 
rabbit anti-GFP (FL) (1:5000 dilution) antibodies were purchased 
from Santa Cruz Biotechnology (Santa Cruz, CA). Monoclonal 
mouse anti-FLAG (M2) (1:2000 dilution), polyclonal rabbit anti-
FLAG (1:2000 dilution), and monoclonal mouse anti-actin (1:5000 
dilution) antibodies were obtained from Sigma-Aldrich. Polyclonal 
rabbit anti-MKRN1 antibody (1:1000 dilution) and polyclonal rab-
bit anti-p14ARF antibodies (A300-340A and A300-342A) (1:1000 
dilution) were purchased from Bethyl Laboratories (Montgomery, 
TX). Monoclonal mouse anti-p14ARF antibody (ab-3) (1:1000 
dilution) was from Labvision (Fremont, CA). Polyclonal rabbit 
anti-p19ARF antibody (ab80) (1:1000 dilution) was from Abcam 
(UK). Monoclonal mouse anti-p14ARF antibody (Cell Signaling) 
and polyclonal rabbit anti-MKRN1 antibody (Bethyl Laboratories) 
were used for immunohistochemistry.
Cell Culture
Human non–small cell lung carcinoma (H1299), embryonic kid-
ney cell line expressing SV40 large T antigen (293T), cervical 
cancer cell line (HeLa), lung fibroblast (IMR90), and human fore-
skin fibroblast (HFF) were obtained from American Type Culture 
Collection (ATCC, Manassas, VA) and grown in Dulbecco’s modi-
fied Eagle medium (DMEM) supplemented with 10% fetal bovine 
serum. IMR90 and HFF cells of passage number 8 or less were used. 
All human gastric cancer cell lines including human stomach adeno-
carcinoma cell line (AGS) and gastric carcinoma cell lines (SNU-
5, SNU-216, SNU638, SNU-668, SNU601, SNU-719, MKN28, 
YCC-2, and KATO-III) were purchased from the Korea Cell Line 
Bank (KCLB, Seoul, Korea) and were grown in RPMI medium sup-
plemented with 10% fetal bovine serum. The ATCC and KCLB 
authenticate the phenotypes of these cell lines on a regular basis.
Cellular and Biochemical Analyses
For the crystal violet staining assay, cells were transfected with 
30 nM siRNA using Lipofectamine RNAiMAX three times, fol-
lowed by one wash with phosphate buffered saline (PBS) and fixa-
tion with 1% glutaraldehyde for 10 min. After washing with PBS, 
cells were stained with 0.5% crystal violet for 10 min at room tem-
perature (RT). For immunoprecipitation assays, cells were plated in 
100-mm dishes and transfected with plasmids using Lipofectamine 
2000 (Invitrogen, Carlsbad, CA). After 24 h of transfection, cells 
were lysed with a lysis buffer (50 mM Tris-HCl [pH 7.5], 150 mM 
NaCl, 0.5% NP-40, 0.5% Triton X-100, 0.1% Na-deoxycholate, 
1 mM EDTA, and protease inhibitors). Lysates were immunopre-
cipitated with antibodies for 2 h at 4°C and incubated with protein 
G-sepharose beads (GE healthcare, Buckinghamshire, UK) for 2 h 
at 4°C. Beads were centrifuged and eluted with 2× sample buffer. 
Immunofluorescence assays were performed as follows: Cells were 
plated in 12-well plates with cover slips. Transfection of plasmids 
was conducted using Lipofectamine 2000. After 24-h transfec-
tion, cells were fixed in 10% paraformaldehyde for 10 min and 
then washed three times with PBS. The fixed cells were permea-
bilized by 0.5% Triton X-100 in PBS for 10 min and washed three 
times with PBS. The cells were blocked with 5% bovine serum 
albumin in PBS for 30 min and incubated with primary antibod-
ies in 2.5% bovine serum albumin overnight. The cells were then 
washed three times for 5 min each prior to incubation with Alexa 
Fluor 488- conjugated anti-mouse or Alexa 594-conjugated anti-
rabbit antibodies (Molecular Probes, Eugene, OR) for 1 h. The 
cells were washed, stained with 4′,6-diamidino-2-phenylindole 
for 10 min, washed again, mounted on slides, and analyzed using 
N-SIM superresolution microscopy. For the cell viability assay, 
H1299, HeLa, AGS, and SNU 601 cells were plated and cultured 
for 24, 48, 72, and 96 h. The cells were incubated with CellTiter-
Glo Reagent (Promega, G7571) for 15 min at 37°C. Luminescence 
was recorded using a luminometer.
Reverse Transcription Polymerase Chain Reaction 
(RT-PCR)
Total RNA was subjected to RT-PCR using p14ARF primers, 
5′-cgg aat tca tgg tgc gca ggt tct tg-3′ (forward) and 5′-cg gaa ttc 
ttt ggt ctt cta gga agc gg-3′ (reverse). MKRN1 primers and PCR 
method were as reported previously (21).
Preparation of MKRN-1 shRNA–Loaded Lentivirus and 
Stable AGS Cell Lines
We prepared stable AGS cell lines with reduced MKRN1 and/
or p14ARF expression by interference with specific shRNAs. 
Lentiviral vectors containing MKRN1 or p14ARF shRNA 
sequences were purchased from Sigma-Aldrich. The lentivirus 
particles were generated by cotransfection of 293FT cells with 
lentiviral vectors and three plasmids, VSVG, RSV-REV, and 
PMDLg/pPRE, using Lipofectamine 2000 transfection reagent 
following the manufacturer’s instructions (Invitrogen). Two days 
after transfection, the cell culture media were filtered using a 0.45-
µm filter. AGS cells were transfected with these lentiviral particles 
and sorted using puromycin. MKRN1 and p14ARF protein and 
mRNA expression levels were determined by western blot and 
RT-PCR analysis, respectively.
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Ubiquitination Assay
Ubiquitination assays were performed under denaturation condi-
tions using Ni2+-nitrilotriacetic acid beads, as reported previously 
(22) as well as by immunoprecipitation of HA/Ub. After the dena-
turation of proteins in cells by sodium dodecyl sulfate (SDS) and 
lysis by lysis buffer (50 mM Tris-HCl [pH 7.5], 150 mM NaCl, 
0.5% NP-40, 0.5% Triton X-100, 0.1% Na-deoxycholate, 1 mM 
EDTA, and protease inhibitors), cell lysates were immunoprecipi-
tated with anti-HA antibody.
SA-β-Galactosidase Assay
The β-galactosidase assay for senescence was performed using a 
senescence detection kit (#K320-250, BioVision, Mountain View, 
CA). Briefly, cells were plated in 60-mm dishes and cultured for 
2–3 days and then washed once with PBS and fixed with fixation 
solution for 15 min at RT. Cells were washed two times with PBS 
and incubated with staining solution overnight at 37°C, followed 
by microscopic analyses.
Preparation of MKRN1 Null MEFs
FVB/NJxC57BL/6J F2 mice with a MKRN1-knockout allele (het-
erozygous mice, +/−) were kindly provided by Drs Deyu Feng and 
TA Gray (Northwestern University and David Axelrod Institute) 
(23). MKRN1+/− mice were further backcrossed until N6 in the B6 
background. Female and male N6 MKRN1+/− mice were crossed 
to produce MKRN1+/+, MKRN1−/− MEFs. To obtain MEFs from 
13.5-day old embryos, embryos were washed using PBS (Welgene) 
and minced. After mincing, MEFs were incubated with 3-ml 
trypsin/EDTA (Gibco) at 37°C for 15 min. Trypsinized MEFs 
were transferred to 150-mm culture dishes, and 20  mL DMEM 
containing 10% fetal bovine serum (GIBCO) was added. The 
dishes were incubated at 37°C for 4–8 h. After 4–8 h, media were 
exchanged, MEFs were retained in DMEM containing 10% fetal 
bovine serum, and they were subcultured at 1:3 ratio upon reaching 
confluence.
In Vivo Gastric Cancer Xenograft Mouse Models
All animal experiments were approved by the Institutional Review 
Board of National Cancer Center (NCC, Korea) and performed 
under specific pathogen-free facilities and conditions in accordance 
with the Guidelines for the Care and Use of Laboratory Animals 
of NCC (NCC-11-034D). Six-week-old female specific pathogen-
free Balb/c nude mice were purchased from Central Lab (Animal 
Inc, Korea). Mice were inoculated subcutaneously into both ﬂanks 
with 106 stable AGS cells into each flank and with 106 SNU601 
cells in each flank under 20 µL of ketamine/rompun (9:1) anesthe-
sia. From palpable tumor formation until termination, tumor sizes 
were measured every 2 or 3 days using calipers, and tumor volume 
was calculated according to the formula, length × width2 × 0.5236. 
Mice were killed in 7.5% CO2 chamber, and tumors were harvested 
for immunohistochemical and other analyses.
Human Gastric Cancer Tissue Microarray Analyses
For immunohistochemical analysis, core tissue biopsy speci-
mens (2-mm diameter) were obtained from individual paraffin-
embedded gastric carcinomas (donor blocks) and arranged in new 
recipient paraffin blocks (tissue array blocks) using a trephine 
apparatus (Superbiochips Laboratories, Seoul, South Korea). 
Immunohistochemical analysis of MKRN1 and p14ARF was per-
formed as described previously (24).
Statistical Analyses
The Pearson correlation coefficient was calculated to estimate the 
colocalization of p14ARF and MKRN1 within cells. We employed 
chi-square test to evaluate the relationship between p14ARF and 
MKRN1 levels in gastric tumor patient tissues. Two tumors per 
mouse were obtained and analyzed as mean tumor volume per 
mouse. Unpaired t tests were used to analyze the tumor volume 
means of xenograft mice. All statistical tests were two-sided, and 
the values were expressed as means with 95% confidence intervals. 
P values of less than .05 were considered to be statistically signifi-
cant. Statistical analyses were performed using Graphpad Prism 
software (version 6; GraphPad Software Inc, La Jolla, CA).
results
MKRN1 Ablation Inhibits Cellular Growth by Increasing 
p14ARF Protein Levels
To understand the possible role of MKRN1 in tumor formation, 
we employed two gastric tumor cancer cell lines, AGS and 
SNU601. The former express wild-type p53, whereas the latter had 
a point mutation of p53 at R273L that renders p53 nonfunctional. 
First, knockdown of MKRN1 was carried out using MKRN1 
siRNA#5 or #6 in both cell lines (Figure 1, A). Because two of the 
MKRN1 siRNAs (#5 and #6) worked equally well, we used #6 in 
the following experiments. Upon ablation of MKRN1, both cells 
exhibited growth retardation and senescence acceleration detected 
using SA-β-galactosidase staining (Figure  1, B and C). Because 
p14ARF is a major tumor suppressor inducing senescence in a p53-
dependent or -independent manner, we tested whether p14ARF 
was affected in the absence of MKRN1. Interestingly, depletion 
of MKRN1 induced stabilization of p14ARF without any effects 
on its mRNA levels (Figure  1, D). When both gene expressions 
were simultaneously depleted (Figure 1, E), the effects of MKRN1 
depletion on cells were annulled by p14ARF ablation, indicating an 
inverse association between MKRN1 and p14ARF (cell growth at 
96 h relative to 24 h: control siRNA vs MKRN1 siRNA: in AGS, 
mean fold change = 2.10 vs 1.39, difference = 0.71, 95% CI = 0.56 
to 0.86, P =  .004; in SNU601, mean fold change = 2.72 vs 1.53, 
difference = 1.19, 95% CI = 0.9 to 1.48, P = .005) (Figure1, F–H). 
We further tested two cancer cell lines with no p53 or nonfunctional 
p53, H1299 (p53 null human lung cancer cells), and HeLa (human 
cervical cancer cells) as described above. In line with the previous 
observations, we observed similar outcomes (Supplementary 
Figure 1, available online). These indicate that ablation of MKRN1 
stabilizes and stimulates the activities of p14ARF, which in turn 
impedes cellular growth with or without functional p53.
Next, the growth and senescence of MKRN1 null and wild-
type MEFs were further analyzed (23). The results indicated that 
53% of MKRN1−/− MEFs that were counted displayed premature 
senescence, whereas only 7.3% of wild-type MEFs went 
through senescence at passage 6 (MKRN1+/+ vs MKRN1−/−, 
mean percentage  =  7.3% vs 53%, difference  =  45.7%, 95% 
CI = 39.07% to 52.33%, P = .005) (Figure 2, A). The protein data 
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comparing both cells exhibited an increase of p19ARF protein 
(Figure 2, B, left panels), whereas there was no detectable change 
of p19ARF mRNA levels (Figure 2, B, right panels). Moreover, 
MKRN1−/− MEFs showed growth retardation compared with 
MKRN1+/+ MEFs (MKRN1+/+ and MKRN1−/− at day 7, mean 
cell number = 8.29 × 105 vs 5.43 × 105, difference = 2.86 × 105, 
95% CI = 2.53 × 105 to 3.19 × 105, P = .003) (Figure 2, C). Based 
on these observations, we investigated the cellular growth and 
senescence of two different human fibroblast cell lines, HFF and 
IMR90 (human fetal lung fibroblasts), in the absence of MKRN1, 
p14ARF, or both. Two MKRN1 siRNAs tested almost completely 
ablated the expression of endogenous MKRN1 (Figure  2, D 
and Supplementary Figure  2, A, available online). Under these 
conditions, each fibroblast cell line displayed retarded cellular 
growth compared with the control. Ablation of p14ARF, with or 
without concurrent MKRN1 knockdown, was able to recover 
cell growth to a level comparable to that of the control (Figure 2, 
E and Supplementary Figure 2, B, available online). Consistently, 
expression of p14ARF in the fibroblasts was increased by MKRN1 
depletion and decreased following treatment with p14ARF 
siRNA, as shown in Figure  2, F and Supplementary Figure  2, 
C, available online (density of p53 relative to control: siRNA vs 
MKRN1 siRNA, mean fold change = 1 vs 1.39, difference = 0.39, 
95% CI  =  0.27 to 0.51, P  =  .01; MKRN1 siRNA vs MKRN1 
siRNA + p14ARF siRNA, mean fold change  =  1.39 vs 1.06, 
difference = 0.33, 95% CI = 0.19 to 0.47, P =  .03, Figure 2, F). 
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Figure 1. MKRN1 knockdown induces cell growth retardation and cel-
lular senescence through p14ARF regulation in gastric cancer cells. A) 
Treatment of MKRN1 siRNAs suppressed the expression of MKRN1. 
After 96-h transfection with control, MKRN1 #5, or MKRN1 #6 siRNAs, 
cell lysates were subjected to immunoblotting using anti-MKRN1 and 
actin antibodies. B) The suppression of cell proliferation in p53 wt AGS 
cells and p53 mutant SNU601 cells under MKRN1 knockdown. After 
treatment with siRNAs as described above, the cells were stained with 
crystal violet. C) Treatment of MKRN1 siRNAs induced cellular senes-
cence. Cells transfected with MKRN1 siRNAs as above were stained 
for β-galactosidase activities. The scale bar indicates 80.26  µm. D) 
Knockdown of MKRN1 induces stabilization of p14ARF without changes 
in mRNA levels of p14ARF. Cells transfected with control or MKRN1 #6 
were analyzed by RT-PCR using primers specific for p14ARF, MKRN1, 
and GAPDH. Cell lysates were analyzed using the antibodies indicated. 
E) MKRN1 siRNA #6 and p14ARF siRNAs treated in AGS and SNU601 
cells suppressed the expression of MKRN1, p14ARF, or both. (F) p14ARF 
depletion blocks the inhibition of gastric cancer cell growth induced 
by MKRN1 ablation. G) Cellular senescence induced by MKRN1 deple-
tion is reversed by p14ARF ablation. The scale bar indicates 80.26 µm. 
All experiments from E) to G) were carried out as described above. H) 
Ablation of p14ARF rescued the cell growth retardation induced by 
MKRN1 depletion. AGS and SNU601 cells were transfected with siRNA 
as indicated. After 24, 48, 72, and 96 h, cell viability was assessed using 
CellTiter-Glo Reagent. The error bars indicate 95% confidence intervals. 
*, P  =  .004; **, P  =  .005 using a two-sided t test. Three independent 
experiments were performed. MKRN1 = Makorin ring finger protein 1; 
p14ARF = p14 alternative reading frame.
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In both cell lines, the levels of p53 were associated with levels of 
p14ARF, underscoring the regulatory role of p14ARF on p53 (25, 
26). SA-β-galactosidase staining assays indicated that depletion 
of MKRN1 accelerated the progression of senescence in both 
fibroblast cell lines and that this was reversed by depletion of 
p14ARF as shown in Figure 2, G and Supplementary Figure 2, D, 
available online (% β-gal-positive cells: control siRNA vs MKRN1 
siRNA, mean percent  =  24.7% vs 62%, difference  =  37.3%, 
95% CI  =  30.67% to 43.93%, P  =  .008; MKRN1 siRNA vs 
MKRN1 siRNA + p14ARF siRNA, mean percent  =  62% vs 
32%, difference = 30%, 95% CI = 27.01% to 32.99%, P = .002, 
Figure  2, G). Although ablation of MKRN1 in both fibroblast 
cell lines induced stabilization of p14ARF and p53, a concurrent 
depletion of MKRN1 and p14ARF did not have a positive effect 
on p53 stability, implying that MKRN1 acts mainly on p14ARF, 
rather than on p53 in these cells.
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Figure  2. Knockout or knockdown of MKRN1 induces senescence 
in MKRN1 KO MEF and HFF cells through the stabilization of ARF. A) 
Premature senescence was induced in MKRN1−/− MEF. MKRN1−/− and 
+/+ MEFs were stained for SA-β-galactosidase activities (×200 magni-
fication). The graph shows the percentage of β-galactosidase-positive 
cells. The error bars indicate 95% confidence intervals. *, P = .005 using 
two-sided t test. Three independent experiments were performed. The 
scale bar indicates 160.51 µm. B) p19ARF was stabilized in MKRN1−/− 
MEFs. Cell lysates of MKRN1−/− and +/+ MEFs were detected with anti-
p19ARF, p53, and MKRN1 antibodies. Cells were analyzed by RT-PCR 
using primers specific for p19ARF, MKRN1, and GAPDH. Arrows indi-
cate MKRN1 and p19ARF proteins. C) MKRN1−/− MEFs showed growth 
retardation. The same amount of MKRN1 +/+ and −/− MEFs was plated 
and counted 1, 2, 3, 4, 5, 6, and 7 days later. The error bars indicate 95% 
confidence intervals. *, P = .003 using two-sided t test. Three independ-
ent experiments were performed. D) Knockdown of MKRN1 suppresses 
growth of HFF cells. After 96-h transfection with control, MKRN1 #6, 
or MKRN1 #7 siRNAs, the cells were stained with crystal violet. Cell 
lysates were subjected to immunoblotting using anti-MKRN1 and actin 
antibodies. The arrow indicates MKRN1. E) p14ARF depletion blocks the 
inhibition of cell growth induced by MKRN1 ablation. HFF cells were 
transfected with control or MKRN1 #6 siRNA, with or without p14ARF 
siRNA. After 96 h, cells were stained with crystal violet. F) p14ARF 
protein is stabilized by MKRN1 depletion. HFF cells were treated as 
indicated, and their lysates were subjected to western blotting using 
antibodies against p14ARF, MKRN1, p53, and actin. The arrow indi-
cates MKRN1. The p53 protein level was quantified using Image-J soft-
ware. The error bars indicate 95% confidence intervals. *, P =  .01; **, 
P  =  .03 using two-sided t test. Three independent experiments were 
performed. G) Cellular senescence induced by MKRN1 depletion is 
reversed by p14ARF ablation. HFF cells were transfected with control 
or MKRN1 #6 siRNA, with or without p14ARF siRNA, as indicated. After 
96 h, cells were stained for β-galactosidase activities (×200 magnifica-
tion). The scale bar indicates 160.51 µm. The graph shows percentage of 
β-galactosidase-positive cells. The error bars indicate 95% confidence 
intervals. *, P = .008; **, P = .002 using two-sided t test. Three independ-
ent experiments were performed. MKRN1 = Makorin ring finger protein 
1; p14ARF = p14 alternative reading frame; p19ARF = p19 alternative 
reading frame; MEFs  =  mouse embryonic fibroblasts; HFF  =  human 
foreskin fibroblast.
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MKRN1 Induces p14ARF Destabilization
Next, we examined an interaction between MKRN1 and p14ARF. 
Both exogenous and endogenous p14ARF and MKRN1 were 
shown to interact by immunoprecipitation assays (Figure 3, A–D). 
We confirmed that MKRN1 directly binds to p14ARF through a 
GST pull-down assay (Figure 3, E). Immunofluorescent analyses 
showed that approximately 88% of p14ARF overexpressed in cells 
is localized to the nucleolus, whereas coexpression of MKRN1 
resulted in relocalization of p14ARF to the nucleoplasm/cytoplasm 
in 72% of cells counted (Figure 3, F). Colocalization analysis using 
NIS-Elements AR software showed a Pearson correlation coeffi-
cient of 0.535 in cytoplasm and 0.708 in nucleoplasm (Figure 3, 
G). Pearson correlation coefficient values indicate that p14ARF 
and MKRN1 are moderately or strongly colocalized in the cyto-
plasm or nucleoplasm, respectively, suggesting that two proteins 
are generally found at the similar localization. Truncation muta-
tion analyses indicated that p14ARF bound to the C-terminus 
of MKRN1, and MKRN1 bound to the N-terminus of p14ARF 
(Supplementary Figure 3, available online).
Because MKRN1 is known to be an E3 ligase, its ability to pro-
mote p14ARF degradation was evaluated (20–22). MKRN1 induced 
degradation of exogenous p14ARF in H1299 cells in a concentra-
tion-dependent manner (Figure  4, A). Experiments employing 
cycloheximide (CHX) treatment to measure the protein half-life 
showed that approximately half of the exogenous p14ARF protein 
disappeared in less than 2 h in the presence of MKRN1, compared 
with almost 5 h without MKRN1 (Figure 4, B). We observed similar 
regulatory effects of MKRN1 on endogenous p14ARF (Figure 4, 
C and D). The fact that MKRN1 depletion increased p14ARF 
protein levels without any noticeable effects on its mRNA levels 
indicates that MKRN1-mediated p14ARF regulation occurs at the 
posttranslational level (Figure 4, E and F). Lastly, MKRN1 abla-
tion prolonged the half-life of endogenous p14ARF, corroborat-
ing the previous data (Figure 4, G). In summary, MKRN1 appears 
to function as a p14ARF repressor by inducing its destabilization 
through posttranslational modification.
MKRN1 Induces p14ARF Ubiquitination and Proteasomal 
Degradation
The effect of proteasome inhibitors, MG132 or LLnL, on the 
MKRN1-mediated p14ARF degradation process indicated that 
MKRN1-mediated degradation of p14ARF is proteasome-depend-
ent (Figure  5, A). Using H307E, an E3 ligase defective form of 
MKRN1 that retains its ability to bind to p14ARF, we further 
demonstrated that the ligase activities of MKRN1 are required for 
p14ARF degradation (Figure 5, B and C) (20). In accordance with 
these data, MKRN1, but not the H307E mutant, was able to medi-
ate ubiquitination of p14ARF (Figure 5, D and E). Furthermore, 
MKRN1 depletion led to decreased levels of endogenous ubiq-
uitinated p14ARF (Figure  5, F). These data demonstrate that 
MKRN1 functions as an E3 ligase to mediate ubiquitination and 
degradation of p14ARF.
There is a restricted functional homology between human 
p14ARF and mouse p19ARF, and these two proteins are known to 
have different binding partners in cells (2, 27, 28). We were able to 
observe an increase of p19ARF in MKRN1 null MEFs (Figure 2, 
B), suggesting a relationship between p19ARF and mouse MKRN1 
(mMKRN1) that is comparable to that between p14ARF and 
human MKRN1. To examine these relationships, we first tested the 
interaction between mMKRN1 and p19ARF. As shown in supple-
mentary Figure 4, A and B, exogenous mMKRN1 and p19ARF do 
bind to each other. Moreover, mMKRN1 also degrades p19ARF 
in a dose-dependent manner (Supplementary Figure  4, C, avail-
able online) through ubiquitination of p19ARF (Supplementary 
Figure 4, D, available online). These showed that human MKRN1 
and mouse MKRN1 display similar suppressive regulation of 
p14ARF and p19ARF, respectively. In conclusion, our data strongly 
indicate that MKRN1 is an E3 ligase that targets ARF as a substrate.
MKRN1 and p14ARF Levels Are Inversely Associated in 
Human Gastric Cancer
To further examine the physiological connection between MKRN1 
and p14ARF, several gastric cancer cell lines were tested for their 
expression levels of MKRN1 and p14ARF. Among 12 cell lines 
tested, 10 lines (indicated by asterisks) display an inverse association 
between protein levels of MKRN1 and p14ARF (Supplementary 
Figure 5, available online). To investigate the clinical implication of 
this relationship, immunohistochemical studies were further per-
formed to evaluate in situ expression of MKRN1 and p14ARF in 59 
gastric cancer tissues. MKRN1 and p14ARF were mainly expressed 
in the cytoplasm and nucleoplasm of cancer cells, although nuclear 
localization of MKRN1 was occasionally detected (Figure 6). Of 57 
gastric carcinoma patients, MKRN1 was expressed in 22 (38.6%) 
and p14ARF in 15 (28.3%). MKRN1 overexpression was statistic-
ally significantly associated with well-differentiated status of gas-
tric carcinoma (P =  .0083, two-sided χ2 test). p14ARF expression 
tended to be associated with poor differentiation and advanced 
staging of gastric carcinoma, although this was not statistically sig-
nificant. Among patients with MKRN1 overexpression, 16 (72.7%) 
showed p14ARF underexpression; these cases were statistically 
significantly associated with a well-differentiated tumor (P = .016, 
two-sided χ2 test) and tended to show association with an earl-
ier stage. Overall, these results indicate that the protein levels of 
MKRN1 and p14ARF display a relatively high inverse association, 
supporting the possible role of MKRN1 as a negative regulator of 
p14ARF in vivo as well as in vitro.
MKRN1 Depletion Suppresses the Formation of Tumors 
in Nude Mice
The biochemical analyses of the effect of MKRN1 on p14ARF 
function led to the hypothesis that MKRN1 plays a critical 
regulatory role in tumor formation. We tested this by constructing 
human gastric cancer AGS cell lines encompassing wild-type p53 
that stably express MKRN1 shRNA #1 or #5, and comparing these 
with control cells (sh-GFP or AGS). Comparison of MKRN1 
expression among these cell lines showed a 50% and 90% decrease 
in MKRN1 protein in lines #1 and #5, respectively (Supplementary 
Figure 6, A, available online). These cell lines were subcutaneously 
injected into the backs of nude mice (n  =  4), and each tumor 
was followed for approximately a month. As anticipated, the 
tumor sizes were inversely associated with the levels of MKRN1 
expression in the stable cell lines (Supplementary Figure 6, B and 
C, available online). The average size of tumors originating from 
cell line #5 with the lowest levels of MKRN1 was one-third of that 
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originating from cell line #1 with medium levels of MKRN1. The 
size of tumors originating from cell line #5 was a sixth of that of 
the controls, whereas tumors originating from cell line #1 were half 
the size of controls. The difference in average size between tumors 
derived from stable cell lines #1 and #5 suggests that the protein 
level of MKRN1 could produce a graded regulatory effect on tumor 
formation. The similarity of tumor sizes between AGS and sh-GFP 
cell lines indicates that lentiviral infection had no major effects on 
tumor growth in xenograft mice inoculated with AGS cells. The 
relationship between MKRN1 and p14ARF protein levels in the 
tumors originating from these cell lines was similar to that those 
previously described for gastric cancers (Supplementary Figure 6, 
D, available online). To test whether the MKRN1 depletion-
mediated growth retardation of xenografted tumor cells was due 
to an increase in p14ARF levels, we next made cell lines that were 
stably transfected with MKRN1 shRNA#5, p14ARF shRNA#1, 
or both (Supplementary Figure  7, A, available online). MKRN1 
knockdown induced a reduction in tumor volume compared with 
the wild type, as shown above. This decrease in tumor volume was 
reversed by a concomitant ablation of p14ARF, suggesting that 
MKRN1 and p14ARF do indeed show an inverse relation. For 
example, mice inoculated with AGS cells displayed mean tumor 
volume of 164.6 mm3 when MKRN1 was ablated (mean tumor 
volume: sh-GFP vs sh-MKRN1#5, 431.8 mm3 vs 164.6 mm3, 
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Figure 3. MKRN1 interacts with p14ARF. A, B) MKRN1 and p14ARF pro-
teins interact with each other. Plasmids expressing HA/MKRN1 alone or 
with p14ARF/FLAG were transfected into 293 cells. WCL were immunopre-
cipitated with anti-FLAG or anti-HA antibodies, and immunoprecipitates 
and WCLs were immunoblotted using the antibodies against MKRN1 and 
p14ARF. C, D) Endogenous MKRN1 and p14ARF bind to each other. HeLa 
cell lysates were immunoprecipitated with anti-p14ARF or MKRN1 anti-
bodies, and immunoprecipitated proteins were analyzed using the same 
antibodies. Arrow indicates p14ARF. E) Recombinant p14ARF and MKRN1 
proteins bind to each other directly. Purified GST/p14ARF and in vitro 
translated HA-MKRN1 were incubated at 37°C (input) followed by pull-
down (PD) using glutathione-sepharose. The precipitated samples were 
detected using anti-MKRN1 and p14ARF antibodies. F) MKRN1 induces 
p14ARF translocation to nucleo/cytoplasm. H1299 cells were transfected 
with plasmids expressing HA/MKRN1 and p14ARF/FLAG. Fixed cells were 
detected by monoclonal anti-HA mouse and polyclonal anti-FLAG rab-
bit antibodies and stained by Alexa Fluor 594-conjugated anti-rabbit and 
Alexa Fluor 488-conjugated anti-mouse antibodies, analyzed using N-SIM 
superresolution microscopy (×150 magnification). The percentages on 
panels 6 and 10 and graph indicate the fractions of counted cells (200) 
that displayed such p14ARF/FLAG localization. G) The Pearson correlation 
coefficient for the colocalization of p14ARF and MKRN1. The error bars 
indicate 95% confidence intervals using two-sided t test. Thirty cells were 
tested for the analyses. The tan bars show the Pearson correlation for 
p14ARF and MKRN1 colocalization. MKRN1 = Makorin ring finger protein 
1; p14ARF = p14 alternative reading frame.
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difference  =  267.2 mm3, 95% CI  =  189.7 mm3 to 344.7 mm3, P = 
.001), whereas tumors with MKRN1 and p14ARF knockdown had 
mean tumor volume of 464.8 mm3 (sh-MKRN1#5 vs sh-p14ARF#1 
+ sh-MKRN1#5, 164.6 mm3 vs 464.8 mm3, difference = 300.2 mm3, 
95% CI = 158.3 mm3 to 442.1 mm3, P = .009) (Figure 7, A and B). 
Next, the tumors from the xenografts were analyzed using 
immunohistochemical studies (Figure 7, C). The data showed that 
depletion of MKRN1 was associated with increased expression 
of p14ARF, with most cells displaying senescence by β-gal 
assay (Figure  7, C, sh-MKRN1#5 panels). On the other hand, 
concomitant depletion of p14ARF and MKRN1 annihilated the 
effects described above (Figure 7, C, panels 4).
Using SNU601 gastric cancer cells containing dysfunctional 
p53 mutant R273L, similar xenograft assays were performed 
as described above to establish MKRN1 effects on p14ARF 
tumorigenesis independent of p53. As with AGS cell lines, stable 
transfections of MKRN1 shRNA#5, p14ARF shRNA#1, or both 
into SNU601  were carried out (Supplementary Figure  7, B, 
available online). The results indicated that depletion of MKRN1 
was able to suppress cell growth, and that this effect was reversed 
by a simultaneous depletion of p14ARF. For example, mice 
inoculated with SNU601 cells with MKRN1 knockdown showed 
mean tumor volume of 158.9 mm3 (mean tumor volume: sh-GFP vs 
sh-MKRN1#5, 321.8 mm3 vs 158.9 mm3, difference = 162.9 mm3, 
Figure  4. MKRN1 induces the degradation of p14ARF. A) MKRN1 
induces the degradation of p14ARF in a dose-dependent manner. H1299 
cells were transfected with mixtures of plasmids expressing p14ARF/
FLAG and HA/MKRN1 with increasing concentrations, or with GFP. The 
cell lysates were detected with anti-FLAG, HA, and GFP antibodies. B) 
MKRN1 decreases the half-life of p14ARF. H1299 cells were transfected 
with mixtures of plasmids expressing p14ARF/FLAG, HA/MKRN1, or GFP 
followed by cycloheximide (CHX) treatment before harvest. The lysates 
were immunoblotted using antibodies against FLAG, HA, and GFP. C) 
Exogenous MKRN1 induces degradation of endogenous p14ARF. HeLa 
cells were transfected with increasing amounts of HA/MKRN1 plasmids. 
The cell lysates were immunoblotted with anti-p14ARF, HA, and actin 
antibodies. D) Exogenous MKRN1 reduces the stability of endogen-
ous p14ARF. HeLa cells were transfected with mock vector or plasmid 
expressing HA/MKRN1 followed by CHX treatment before harvest. The 
cell lysates were immunoblotted with anti-p14ARF, HA, and actin anti-
bodies. E) MKRN1 depletion stabilizes endogenous p14ARF. HeLa cells 
were transfected with control, MKRN1 #5, or MKRN1 #6 siRNAs and 
lysed after 48 h. WCL were immunoblotted with anti-p14ARF, MKRN1, 
and actin antibodies. F) MKRN1 ablation does not affect p14ARF mRNA 
levels. HeLa cells were treated as above and analyzed by RT-PCR using 
primers specific for p14ARF, MKRN1, and GAPDH. G) MKRN1 depletion 
increases stability of endogenous p14ARF. HeLa cells were transfected 
with control and MKRN1 siRNAs followed by treatment with CHX and 
were then lysed and immunoblotted with anti-p14ARF, MKRN1, and 
actin antibodies. The graphs indicate the relative amounts of p14ARF 
protein compared with the levels of actin or GFP in the western blot. The 
expression of each protein was analyzed using the Image J program. 
MKRN1 = Makorin ring finger protein 1; p14ARF = p14 alternative read-
ing frame; CHX = cycloheximide; WCL = whole cell lysates.
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95% CI = 104.24 mm3 to 221.56 mm3, *: P =.01), whereas tumors 
with MKRN1 and p14ARF knockdown displayed 262.6 mm3 
(sh-MKRN1#5 vs sh-p14ARF#1 + sh-MKRN1#5, 158.9 mm3 vs 
234.9 mm3, difference = 76 mm3, 95% CI = 38.71 mm3 to 107.29 mm3, 
P = .02) (Figure 8, A and B). The depletion of MKRN1, p14ARF, 
or both proteins was detected using immunohistochemical studies, 
and the cell senescence was further confirmed using β-gal analyses 
(Figure  8, C), which exhibited comparable results as shown in 
Figure 7. Overall, the data suggest that depletion of MKRN1 could 
enhance p14ARF function, which led to the hampering of cell 
growth both in p53 functional and nonfunctional cell lines.
Discussion
Genetic studies of mice demonstrated that the absence of p19ARF 
results in the development of tumors such as sarcoma, lymphoma, 
and carcinoma at early ages (10, 11). Similar to these observations, 
p14ARF expression is suppressed in numerous cancers, includ-
ing gastric tumors, due to silencing of its expression by promoter 
hypermethylation or allelic loss (13, 29–32). The recent discovery 
of the ULF, which induces p14ARF degradation, highlighted post-
translational regulatory mechanisms, but the direct effects on tur-
morigenesis remain unknown (33).
In this study, we introduce MKRN1 as a novel E3 ligase of 
p14ARF that affects gastric cancer development. Premature senes-
cence with p19ARF stabilization in MKRN1−/− MEF suggests that 
MKRN1 might regulate ARF-induced cellular senescence. The 
importance of the regulatory role of MKRN1 in p14ARF stability 
is emphasized by the observation that p14ARF becomes stabilized 
upon MKRN1 ablation, resulting in growth retardation of both 
human fibroblasts and gastric cancer cells. Moreover, MKRN1 
ablation suppressed gastric tumor formation in xenografted mice, 
Figure 5. MKRN1 functions as an E3 ligase by inducing ubiquitination 
and subsequent proteasomal degradation of p14ARF. A) MKRN1 induces 
proteasomal degradation of p14ARF. H1299 cells were transfected with 
mixtures of plasmids expressing p14ARF/FLAG, HA/MKRN1, or GFP fol-
lowed by 3-h treatment with 20 µM MG132 or LLnL. The lysates were 
immunoblotted with anti-FLAG, HA, and GFP antibodies. B) E3 ligase 
activity of MKRN1 is required for p14ARF degradation. H1299 cells were 
transfected with mixtures of plasmids expressing p14ARF/FLAG, HA/
MKRN1, HA/H307E (E3 ligase activity–deficient mutant), or GFP. The cell 
lysates were immunoblotted using anti-FLAG, HA, and GFP antibodies. 
C) Both MKRN1 WT and H307E interact with p14ARF. Mixtures of plas-
mids expressing p14ARF/FLAG, HA/MKRN1, or HA/H307E were trans-
fected into 293T cells followed by immunoprecipitation using anti-HA 
antibodies and detection of the immunoprecipitated proteins with anti-
FLAG and HA antibodies. D) MKRN1 ubiquitinates p14ARF. H1299 cells 
were transfected with mixtures of plasmids expressing His/Ub, p14ARF/
FLAG, HA/MKRN1, or mock as indicated, with or without MG132. The cell 
lysates were pulled down with Ni2+-NTA resin and detected using anti-HA 
and FLAG antibodies. E) MKRN1 H307E is defective in inducing p14ARF 
ubiquitination. H1299 cells were transfected with mixtures of plasmids 
expressing His/Ub, p14ARF/FLAG, HA/MKRN1, or mock as indicated. 
The cell lysates were pulled down with Ni2+-NTA resin and detected with 
anti-FLAG and HA antibodies. F) MKRN1 depletion suppresses ubiquit-
ination of endogenous p14ARF. HeLa cells were transfected with control 
or MKRN1 siRNAs followed by MG132 treatment. The cell lysates were 
immunoprecipitated with anti-p14ARF antibodies, and the immunopre-
cipitates were detected with anti-p14ARF and HA ubiquitin antibodies. 
All of the ubiquitination analyses were performed under conditions of 
denaturation. MKRN1  =  Makorin ring finger protein 1; p14ARF  =  p14 
alternative reading frame; Ni2+-NTA = Ni2+-nitrilotriacetic acid.
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Figure  6. Protein levels of MKRN1 and p14ARF in malignant tissues 
of gastric cancer patients. In situ expression of MKRN1 and p14ARF in 
gastric cancer tissues was detected by immunohistochemical analysis 
and hematoxylin and eosin (H&E) staining as described in “Materials 
and Methods” (magnification: left, ×40; right, ×200). The upper two 
cases are well-differentiated adenocarcinomas, and the lower one 
is a poorly differentiated adenocarcinoma. The scale bars indicate 
200 µm (×40) and 40 µm (×200). MKRN1 = Makorin ring finger protein 
1; p14ARF = p14 alternative reading frame.
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Figure  7. The suppressive effect of MKRN1 on tumor growth was 
rescued by p14ARF depletion. A–C) Mice (N  =  6) were inoculated 
subcutaneously into both ﬂanks with 106 cells of each AGS cell line. 
Lentiviruses expressing sh-RNA targeting p14ARF, MKRN1, or both 
were employed to produce stable AGS cell lines. Lentivirus express-
ing sh-RNA targeting GFP was used as a control. A) At 23 days after 
inoculation, mice were killed in 7.5% CO2 chamber, and mice and 
excised tumors from mice were photographed. B) Quantification of 
tumor formation was performed by measurement of tumor size 7, 9, 
12, 14, 16, 18, and 20  days after inoculation (N  =  6). The error bars 
indicate 95% confidence intervals. *, P = .001; **, P = .009, two-sided 
t test. All statistical tests were two-sided. C) Immunohistochemical 
analysis and hematoxylin and eosin (H&E) staining were performed 
for each group of tumors as described in “Materials and Methods” 
(magnification ×100). SA-β-galactosidase-stained slides were viewed 
under ×100 and ×200 magnification. The scale bar indicates 100 µm. 
MKRN1  =  Makorin ring finger protein 1; p14ARF  =  p14 alternative 
reading frame.
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which was reversed under depletion of p14ARF with independent 
p53 function.
Upon these results, one crucial issue of MKRN1 regulatory 
pathways is how MKRN1 determines a major target among its 
multiple substrates that include p14ARF, p53, and p21. Because 
we previously reported that MKRN1 mediates p53 and p21 deg-
radation through the ubiquitination and proteasome-dependent 
degradation pathways (21), interestingly, it appears that ablation of 
MKRN1 induced p14ARF and p53 at the same time, as expected, 
whereas a simultaneous knockdown of p14ARF and MKRN1 
was not able to induce p53. These observations indicate that the 
MKRN1-dependent p53 degradation might be overruled by a 
more dominant MKRN1-dependent p14ARF regulation, at least 
in the cell lines used here. Further experiments using p53 dys-
functional or null gastric cancer cells indicated that MKRN1 
knockdown was capable of inducing p14ARF stabilization with 
concurrent cell growth retardation. These data suggest possible 
physiological roles of MKRN1 and p14ARF in regulating gastric 
tumorigenesis without p53 functions. The central importance of 
the interaction between p14ARF and MKRN1 was more clearly 
demonstrated by the xenografted mice data, showing an eruption 
of tumor growth upon the ablation of p14ARF in AGS gastric can-
cer cells expressing wild-type p53 in which growth was otherwise 
retarded by the absence of MKRN1. Because the system employed 
here cannot exclude the possible role of p53 in coordination with 
p14ARF in reversing MKRN1-dependent retardation of tumor 
growth, SNU601 gastric cancer cells with dysfunctional p53 were 
tested in xenografted mice analyses. This cell line has mutation 
of p53 on residue 273 from arginine to leucine, which is known 
as a hot spot in various cancer cells (34,35). MKRN1 depletion–
mediated tumor-suppressive function was rescued by p14ARF 
ablation in this cell line. It indicates that MKRN1 could mediate 
tumorigenesis via p14ARF regulation without functional p53 and 
suggests that MKRN1 inhibition might be a meaningful target 
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Figure 8. The tumor-suppressive effects of MKRN1 knockdown via sta-
bilization of p14ARF were observed in the p53 mutated gastric cancer 
cell line SNU601. A–C) Mice (N = 4) were inoculated subcutaneously in 
both ﬂanks with 106 cells of each SNU601 cell line. The stable SNU601 
cell lines were prepared in the same ways as mentioned in Figure 7. A) At 
23 days after inoculation, mice were killed in 7.5% CO2 chamber, and mice 
and excised tumors from mice were photographed. B) Quantification of 
tumor formation was performed by measurement of tumor size 4, 6, 
8, 11, and 13 days after inoculation (N = 4 tumors for four mice). The 
error bars indicate 95% confidence intervals. *, P = .02; **, P = .01, two-
sided t test. All statistical tests were two-sided. C) Immunohistochemical 
analysis and hematoxylin and eosin (H&E) staining were performed for 
each group of tumors as described in Materials and Methods (magni-
fication ×200). SA-β-galactosidase-stained slides were viewed under 
×200 magnification. The scale bar indicates 100 µm. MKRN1 = Makorin 
ring finger protein 1; p14ARF = p14 alternative reading frame.
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for cancer therapy through p14ARF activation in tumors with 
nonfunctional p53.
This study also had some limitations. Because there are diverse 
combinations of p53 mutations or deletion with epigenetic sup-
pression of p14ARF proteins in human tumors (12–16), target-
ing of MKRN1 for tumor therapy could be limited to tumors 
displaying similar cellular context as the gastric cancer cells 
investigated above.
Taken together, we can draw noteworthy conclusion from these 
observations that MKRN1 E3 ligase remains unique in its ability 
to negatively regulate the major tumor suppressors including 
p14ARF and p53 (21). This indicates a possible role of MKRN1 as a 
potentially meaningful oncogene. The human gastric tumor tissue 
array data corroborate this notion, showing an inverse association 
between MKRN1 and p14ARF in approximately half of the gastric 
cancer tissues tested. However, we were not able to determine the 
associations between p53, MKRN1, and p14ARF because up to 
60% of patient samples examined displayed p53 mutant expression, 
consistent with a previous report of p53 mutation frequency in 
gastric cancer (35).
Our results verified MKRN1 as an ubiquitin E3 ligase of 
p14ARF. The data presented strongly indicate that MKRN1 could 
instigate tumorigenesis by regulating the p14ARF-associated path-
ways and thus potentially represents an important therapeutic tar-
get in gastric tumors.
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